MERCK KGAA

CEACAM5 drugs market to grow significantly due to rising cancer diagnoses and clinical trials; no CEACAM5 drugs currently approved. Key companies developing CEACAM5 drugs include Merck KGaA, Sanofi, and Roche. Emerging therapies like SGM-101 and M9140 show promise in clinical trials.

The report by MarketandResearch.biz analyzes the global Pharmaceutical & Biotechnology Environmental Monitoring market, focusing on growth, technological advancements, key players, and regional demand from 2015 to 2032.

The Renal Cell Carcinoma Clinical Trial Pipeline Market is projected to grow significantly from 2024 to 2031, driven by technological innovations, rising demand, and regulatory changes. The market is segmented by type and application, with key players including Amgen, AstraZeneca, and Pfizer. Clinical trials focus on novel therapies, drug combinations, and targeted treatments, aiming to improve outcomes for renal cell carcinoma patients.

Bicara Therapeutics raised $315 million in IPO to fund a pivotal study for its head and neck cancer therapy, ficerafusp alfa, which targets EGFR and TGF-beta signaling. The drug, combined with Keytruda, showed a 54% overall response rate in advanced HNSCC patients, with 64% in HPV-negative cases. A Phase 2/3 trial is planned for 2025.

The United States Chromatography in Biotechnology Market is projected to reach USD xx.x billion by 2031, with a CAGR of xx.x% from 2024 to 2031. The market is segmented by type, including liquid chromatography (LC), gas chromatography (GC), ion exchange chromatography (IEC), affinity chromatography (AC), and size exclusion chromatography (SEC). Key manufacturers include Bio-Rad Laboratories Inc, Danaher Corp., MilliporeSigma, Qiagen, Scion Instruments, Thermo Fisher Scientific Inc, Perkinelmer, GE Healthcare Life Sciences, Antec Scientific, and Asynt Ltd. Technological advancements are expected to enhance product performance and adoption in various applications.

MilliporeSigma launches the first single-use Mobius® ADC Reactor for antibody drug conjugate (ADC) manufacturing, increasing efficiency by 70% and using Ultimus® Film for superior leak resistance.

The global pharmaceutical filtration market is projected to grow from USD 12.47 billion in 2023 to USD 19.55 billion by 2033, driven by drug launches and R&D activities. North America leads with a 36.17% share, and membrane filters dominate the product type segment. Microfiltration is expected to grow at the fastest CAGR of 6.75%. Final product processing holds the largest market share of 22.54%. Challenges include high capital requirements and increased regulations.

MilliporeSigma launches Mobius ADC Reactor, a single-use reactor for antibody drug conjugate (ADC) production, addressing unique manufacturing challenges with faster turnaround times and reduced contamination risk. The reactor features Ultimus Film technology for enhanced durability and quality.

BioNxt Solutions Inc. reports positive EPO examination for sublingual anticancer drug delivery patent, expecting EU grant within 8 weeks. The company plans to extend its patent portfolio for orally dispersible films containing potent anticancer compounds, targeting neurodegenerative diseases and filing related patents globally by late 2025. BioNxt's lead program focuses on a proprietary ODF Cladribine dosage form for multiple sclerosis, with additional clinical indications planned for Myasthenia Gravis. The market for CNS disease treatments is projected to reach USD 238.8 billion by 2032.